Evidence map›Paper›PMID 38773124›Full record

ArticleNPJ Parkinson's disease2024

Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy.

Sara Walton, Alexis Fenyi, Tyler Tittle, Ellen Sidransky, Gian Pal, Solji Choi, Ronald Melki, Bryan A Killinger, Jeffrey H Kordower

Abstract read
In one paragraph

Article in NPJ Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Sara WaltonASU-Banner Neurodegenerative Disease Research Center and School of Life Sciences, Arizona State University, Tempe, AZ, USA.ORCID http://orcid.org/0000-0002-4981-0309
Alexis FenyiInstitut Francois Jacob (MIRCen), CEA and Laboratory of Neurodegenerative Diseases, CNRS, Fontenay-Aux-Roses Cedex, France.
Tyler TittleGraduate College, Rush University Medical Center, Chicago, IL, USA.
Ellen SidranskyMedical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Gian PalDepartment of Neurology, Division of Movement Disorders, Rutgers - Robert Wood Johnson Medical School, New Brunswick, NJ, USA.ORCID http://orcid.org/0000-0003-1048-6182
Solji ChoiGraduate College, Rush University Medical Center, Chicago, IL, USA.
Ronald MelkiInstitut Francois Jacob (MIRCen), CEA and Laboratory of Neurodegenerative Diseases, CNRS, Fontenay-Aux-Roses Cedex, France.ORCID http://orcid.org/0000-0003-0000-7096
Bryan A KillingerGraduate College, Rush University Medical Center, Chicago, IL, USA. Bryan_killinger@rush.edu.ORCID http://orcid.org/0000-0002-8043-8517
Jeffrey H KordowerASU-Banner Neurodegenerative Disease Research Center and School of Life Sciences, Arizona State University, Tempe, AZ, USA.ORCID http://orcid.org/0000-0001-8629-3294

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Devalingam Mahalingam · 1993 to 2026
$153.9M
Genetic and clinical studies of Gaucher disease and other lysosomal disordersZIAHG200336 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI SIDRANSKY, ELLEN · 2009 to 2025
$45.2M
TR&D 7: Cell Specific ProteomicsP41GM108569 · NIGMS · NORTHWESTERN UNIVERSITY · PI KELLEHER, NEIL L · 2015 to 2024
$13.6M
PROTEOMIC MAPPING OF PATHOLOGICAL INTERACTIONS ACROSS THE SYNUCLEINOPATHY BRAINR01NS128467 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI KILLINGER, BRYAN · 2022 to 2024
$1.0M
Parkinson disease and DBS: cognitive effects in GBA mutation carriersK23NS097625 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI PAL, GIAN D · 2017 to 2021
$936k
Acquisition of a Thermo Fisher Scientific Q Exactive UHMR mass spectrometerS10OD025194 · OD · NORTHWESTERN UNIVERSITY · PI COMPTON, PHILIP DANIEL · 2018 to 2018
$795k
Does alpha synuclein strain or GCase enzyme activity drive clinical aggression in GBA-PD?R21NS109871 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI KORDOWER, JEFFREY H · 2018 to 2019
$432k
Michael J. Fox Foundation for Parkinson's Research (Michael J. Fox Foundation) ASAP-000458NCI NIH HHS P30 CA060553NIGMS NIH HHS P41 GM108569NIH HHS S10 OD025194NINDS NIH HHS K23 NS097625NINDS NIH HHS R01 NS128467NINDS NIH HHS R21 NS109871U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) 1R01NS128467U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) 5R21NS109871U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) K23-NS097625-06
6 · The paper itself

Abstract

Parkinson's disease (PD) is a neurodegenerative disease characterized by progressive motor symptoms and alpha-synuclein (αsyn) aggregation in the nervous system. For unclear reasons, PD patients with certain GBA1 mutations (GBA-PD) have a more aggressive clinical progression. Two testable hypotheses that can potentially account for this phenomenon are that GBA1 mutations promote αsyn spread or drive the generation of highly pathogenic αsyn polymorphs (i.e., strains). We tested these hypotheses by treating homozygous GBA1 D409V knockin (KI) mice with human α-syn-preformed fibrils (PFFs) and treating wild-type mice (WT) with several αsyn-PFF polymorphs amplified from brain autopsy samples collected from patients with idiopathic PD and GBA-PD patients with either homozygous or heterozygous GBA1 mutations. Robust phosphorylated-αsyn (PSER129) positive pathology was observed at the injection site (i.e., the olfactory bulb granule cell layer) and throughout the brain six months following PFF injection. The PFF seeding efficiency and degree of spread were similar regardless of the mouse genotype or PFF polymorphs. We found that PFFs amplified from the human brain, regardless of patient genotype, were generally more effective seeders than wholly synthetic PFFs (i.e., non-amplified); however, PFF concentration differed between these two studies, which might also account for the observed differences. To investigate whether the molecular composition of pathology differed between different seeding conditions, we performed Biotinylation by Antibody Recognition on PSER129 (BAR-PSER129). We found that for BAR-PSER129, the endogenous PSER129 pool dominated identified interactions, and thus, very few potential interactions were explicitly identified for seeded pathology. However, we found Dynactin Subunit 2 (Dctn2) interaction was shared across all PFF conditions, and NCK Associated Protein 1 (Nckap1) and Adaptor Related Protein Complex 3 Subunit Beta 2 (Ap3b2) were unique to PFFs amplified from GBA-PD brains of heterozygous mutation carriers. In conclusion, both the genotype and αsyn strain had little effect on overall seeding efficacy and global PSER129-interactions.

Identifiers

PMID38773124
PMCPMC11109094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.